Opinion on Drug Delivery

Published within

« | ... | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Wyeth/MedImmune: second generation vaccine

Wyeth [WYE] and MedImmune's [MEDI] FluMist failed to secure indications for use in key target groups for influenza vaccine in the US. Recently released results suggest that their second generation product may enable the two companies to capitalize on more conventional influenza vaccine sectors.

Published By Datamonitor
15 Oct 2003
CommentWire
CommentWire

Wyeth/MedImmune: the end of the road for FluMist venture

Following poor first-year performance, Wyeth [WYE] and MedImmune [MEDI] have announced the dissolution of their FluMist partnership. If MedImmune is to achieve success with this product alone, it may need to rethink its premium pricing strategy.

Published By Datamonitor
28 Apr 2004
CommentWire
CommentWire

Wyeth: wider benefits for Prevnar

Research from Kaiser Permanente suggests that widespread immunization with Prevnar reduces the incidence of pneumococcal infections in adults and older children. This and other similar studies should help to establish greater demand for Prevnar, which has yet to entirely fulfill its potential due to its relatively high cost.

Published By Datamonitor
05 May 2004

« | ... | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | » »|

No help is available.